Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 5/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29834690 | 0.89 | KDM4E (0.42) | RAF1P2RX3BRAFGRM5KDR | |
| SCHEMBL6425243 | 0.89 | KDM4E (0.42) | RAF1P2RX3BRAFGRM5KDR | |
| SCHEMBL28407664 | 0.87 | GRM5 (0.40) | RAF1SCN9ABRAFGRM5HRH3 | |
| Methylamine SCHEMBL28986184 | 0.86 | PYGL (0.41) | RAF1P2RX3BRAFGRM5ABL1 | |
| SCHEMBL29834761 | 0.85 | P2RX3 (0.43) | RAF1P2RX3BRAFGRM5ABL1 | |
| SCHEMBL4328868 | 0.85 | P2RX3 (0.43) | RAF1P2RX3BRAFGRM5ABL1 | |
| Formamide SCHEMBL28986166 | 0.84 | KDR (0.41) | RAF1P2RX3BRAFGRM5ABL1 | |
| SCHEMBL19627828 | 0.84 | RAF1 (0.39) | RAF1P2RX3BRAFGRM5ABL1 | |
| SCHEMBL400592 | 0.84 | KDR (0.58) | RAF1BRAFABL1KDRMET | |
| SCHEMBL29396481 | 0.84 | KDR (0.58) | RAF1BRAFABL1KDRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103415514-B | Process for producing phenoxypyridine derivative | Sanitary Material R&D Management Co.,Ltd. (JP) | 2015-09-30 | — | — | CN | disclosed |
| EP-2073811-B1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8759530-B2 | Method for producing phenoxypyridine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-24 | — | — | US | disclosed |
| EP-2692725-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-02-05 | — | — | EP | disclosed |
| US-20140011999-A1 | Method for Producing Phenoxypyridine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-01-09 | — | — | US | disclosed |
| CN-103415514-A | Process for producing phenoxypyridine derivative | EISAI R&D MAN CO LTD | 2013-11-27 | — | — | CN | disclosed |
| CN-102421771-B | Pyridone amide derivative, preparation method and medical application thereof | UNITRIS BIOPHARMA CO LTD | 2013-11-20 | — | — | CN | disclosed |
| US-8586565-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| EP-1889836-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | EISAI R&D MAN CO LTD (JP) | 2013-06-12 | — | — | EP | disclosed |
| CN-101553233-B | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS LLC | 2013-05-29 | — | — | CN | disclosed |
| WO-2008046003-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | WO | disclosed |
| EP-1889836-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | Eisai R&D Management Co., Ltd. (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1719763-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1719762-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | RAF1 162/4885SCN9A 2324/4885P2RX3 662/4885 |
| US-20140011999-A1 | Method for Producing Phenoxypyridine Derivative | QDPR, DRD4, DOT1L | RAF1 1832/4885SCN9A 619/4885P2RX3 2368/4885 |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | HGF, MET, HDGF | RAF1 145/4885SCN9A 1992/4885P2RX3 692/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | RAF1 142/4885SCN9A 4354/4885P2RX3 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.